20.500.12556/RUL-168504 Telomere length and oxidative stress in small cell lung cancer patients changes through chemotherapy cycles compared to healthy controls Introduction: Small cell lung cancer (SCLC) is an aggressive malignant disease with poor survival outcomes. The aim of this study was to investigate leukocyte telomere length (LTL) and redox status parameters during chemotherapy and evaluate their prognostic potential based on the hypothesis that shorter LTL and oxidative stress burden correlate with poorer survival. Materials and methods: This longitudinal study included 60 SCLC patients and 73 healthy controls. Leukocyte telomere length was measured by quantitative PCR (qPCR) method, while redox status parameters (MDA - malondialdehyde, IMA - ischemia-modified albumin, PON1 - paraoxonase 1, redox index) were determined by spectrophotometric methods before, after two and after four cycles of chemotherapy. Results: All measured parameters showed significant differences between patients and controls, except the oxy-score (P < 0.001). Significant differences in IMA, PON1 and redox index were observed between SCLC patient groups at different time points (P < 0.001). Significant differences in IMA and PON1 were observed between SCLC survival groups, with higher values found in survivors after two chemotherapy cycles (P < 0.001). Redox index was the highest in the pre-chemo group (P = 0.019). Among patients who died, PON1 activity differed significantly between those who died within 2 months and after 4 months (P = 0.028). Kaplan-Meier analysis showed that LTL and PON1 were significant predictors of survival, with values below the 25th percentile associated with a higher risk of death. Conclusions: Leukocyte telomere length and PON1 are potential prognostic biomarkers for SCLC survival, suggesting their potential use in non-invasive biomarker panels for improved patient stratification. telomere length redox status small cell lung cancer cisplatin/etoposide regimen dolžina telomera redoks stanje drobnocelični pljučni rak režim cisplatin/etopozid rak (medicina) pljuča true false true Angleški jezik Slovenski jezik Članek v reviji 2025-04-16 09:16:55 2025-04-16 09:16:59 2025-04-17 04:54:33 0000-00-00 00:00:00 2025 0 0 12 str. issue 2, art. 020705 Vol. 35 2025 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 616.24-006 1846-7482 10.11613/BM.2025.020705 232858115 RAZ_Guzonjic_Azra_2025.pdf RAZ_Guzonjic_Azra_2025.pdf 1 AAD39BDF65ADACACBB41F0522F3C0406 1682c78aab22829be23428f278e74b1b5a5d47aefede6dd156078f3c7b02751d a9c52e2f-1a91-11f0-b232-0050569b8976 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=203453 https://biochemia-medica.com/en/journal/35/2/10.11613/BM.2025.020705 1 a97fee7d-1a91-11f0-b232-0050569b8976 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=203452 Fakulteta za farmacijo 0 0 0